Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Recruiting × Miransertib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Proteus Syndrome 1

Interventions

pembrolizumab 209 Carboplatin 196 Specimen Handling 174 Cisplatin 171 Magnetic Resonance Spectroscopy 152 Radiotherapy 131 Bevacizumab 123 Gemcitabine 115 Cyclophosphamide 112 Drug Therapy 107 Capecitabine 104 Paclitaxel 100 Nivolumab 99 venetoclax 97 Oxaliplatin 91 Biopsy 89 durvalumab 75 Rituximab 75 tislelizumab 73 toripalimab 64 Fluorouracil 64 Etoposide 63 Radiosurgery 62 Docetaxel 62 atezolizumab 60 Pemetrexed 60 Dexamethasone 59 Azacitidine 56 lenvatinib 55 130-nm albumin-bound paclitaxel 53

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04316546 2026-03-11

MK-7075 (Miransertib) in Proteus Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting

Proteus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡